Product image of Glymetia (Metformin Hydrochloride, Linagliptin) supplied by GNH India

Glymetia

Active Ingredient:
Metformin Hydrochloride, Linagliptin
Origin:
EU

Glymetia (Metformin Hydrochloride, Linagliptin)

Glymetia is a prescription oral medication that combines metformin hydrochloride and linagliptin in a single tablet. The product belongs to the biguanide/DPP‑4 inhibitor combination class and is indicated for the management of type 2 diabetes mellitus. It is marketed in the European Union and is available only with a physician’s prescription. Each dose delivers an amount of metformin and linagliptin to improve glycemic control when used with diet and exercise.

Manufacturer / TM Owner

Pharmapath Sa

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Glymetia is prescribed as part of a comprehensive treatment plan for adults with type 2 diabetes.

  • Improves fasting and post‑prandial blood glucose levels when combined with diet and exercise.
  • Provides dual pharmacologic action: metformin reduces hepatic glucose output, while linagliptin enhances incretin activity.
  • May be used when metformin monotherapy does not achieve glycemic targets.
  • Can be considered for patients who require an additional oral agent without initiating insulin therapy.

Side Effects

The safety profile of Glymetia reflects the known effects of its two components, metformin and linagliptin.

Common

  • Nausea or upset stomach.
  • Diarrhea or loose stools.
  • Headache.
  • Upper respiratory tract infection symptoms.

Serious

  • Lactic acidosis (rare, associated with metformin).
  • Severe hypersensitivity reactions such as skin rash or angioedema.
  • Pancreatitis (rare, linked to DPP‑4 inhibition).

Precautions & Warnings

Clinicians should evaluate patient-specific factors before initiating Glymetia to minimize risks and ensure appropriate use.

  • Assess renal function; metformin is contraindicated in severe renal impairment.
  • Monitor liver enzymes, as hepatic disease may increase risk of lactic acidosis.
  • Use caution in patients with a history of heart failure.
  • Avoid use during pregnancy and breastfeeding unless benefits outweigh risks.
  • Review concomitant medications that may affect renal clearance or increase hypoglycemia risk.
  • Adjust dose in elderly patients due to altered pharmacokinetics.

Avoid Interactions

Glymetia can interact with several medicines; understanding these interactions helps prevent adverse events.

Avoid

  • Concurrent use of other metformin‑containing products (risk of overdose).
  • Strong CYP3A4 inhibitors (e.g., ketoconazole) that may increase linagliptin exposure.
  • Iodinated contrast agents used for imaging in patients with reduced renal function (risk of metformin‑associated lactic acidosis).

Use with caution

  • Diuretics that may affect renal function and metformin clearance.
  • Beta‑blockers or other antihypertensives that mask hypoglycemia symptoms.
  • Alcohol consumption, which can potentiate metformin’s effect on lactate metabolism.

Frequently Asked Questions

Glymetia combines metformin, which lowers hepatic glucose production and improves insulin sensitivity, with linagliptin, a DPP‑4 inhibitor that raises endogenous incretin levels to enhance glucose‑dependent insulin secretion.

Glymetia may be used with dose adjustment in mild renal impairment, but it is contraindicated in severe renal dysfunction. Renal function should be assessed before starting therapy.

Glymetia can be added to insulin regimens when additional oral glucose‑lowering is needed, but dose adjustments of insulin may be required to avoid hypoglycemia.

If a dose is missed, the patient should take it as soon as they remember unless it is close to the time of the next scheduled dose. They should not double‑dose.

Patients should follow a balanced diet and limit excessive alcohol intake, as alcohol can increase the risk of metformin‑related lactic acidosis.

Blood glucose should be monitored regularly as directed by the healthcare provider, typically fasting and post‑prandial measurements to assess therapeutic response.

The safety of Glymetia in pregnancy has not been established; it should only be used if the potential benefit justifies the potential risk to the fetus.

Symptoms include unusual muscle pain, trouble breathing, abdominal discomfort, dizziness, or feeling cold and clammy. Prompt medical evaluation is essential.

Antacids containing aluminum or magnesium may slightly reduce linagliptin absorption; spacing the doses by at least 2 hours can minimize this effect.

Glymetia is typically initiated at a fixed dose; however, clinicians may adjust the metformin component based on tolerability and renal function.

A severe or spreading rash may indicate a hypersensitivity reaction; the patient should discontinue the medication and seek immediate medical care.

Glymetia provides a fixed‑dose combination, simplifying the regimen and potentially improving adherence compared with taking two separate tablets.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT